Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro

Biomedicine and Pharmacotherapy

Volumn 63, Issue 8, 2009, Pages 553-560

  Yanagie, Hironobu ^a,b   Hisa, Tomoyuki ^b   Ogata, Aya ^b   Miyazaki, Ayaka ^b   Nonaka, Yasumasa ^c   Nishihira, Teturo ^d   Osada, Isao ^d   Sairennji, Takayuki ^d   Sugiyama, Hirotaka ^b   Furuya, Yoshitaka ^e   Kidani, Yosinori ^f   Takamoto, Shinichi ^b   Takahashi, Hiroyuki ^a,b   Eriguchi, Masazumi ^b,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c Hoyo Hospital   (Japan)

^d Department of Surgery   (Japan)

^e Satukidai Hospital   (Japan)

^f Kidani Memorial Foundation   (Japan)

^g SHOWA UNIVERSITY   (Japan)

Author keywords

CITED2; Drug resistance; TBCE

Indexed keywords

BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN P300 INTERACTING TRANSACTIVATOR 2 PROTEIN; DIPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE P1; MESSENGER RNA; METALLOTHIONEIN; OXALIPLATIN; PLATINUM COMPLEX; SMALL INTERFERING RNA; TUBULIN SPECIFIC CHAPERONE E; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH CANCER; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYSTADENOCARCINOMA, SEROUS; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MOLECULAR CHAPERONES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TRANS-ACTIVATORS; TRANSFECTION; UP-REGULATION;

EID: 70349307507     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.04.006     Document Type: Article

References (55)

1. Kikuchi Y., Miyauchi M., Kizawa I., Oomori K., and Kato K. Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 77 6 (1986 Dec) 1181-1185
2. Kikuchi Y., Hirata J., Yamamoto K., Ishii K., Kita T., Kudoh K., et al. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res 88 (1997) 213-217
3. Sakamoto M., Kondo A., Kawasaki K., Goto T., Sakamoto H., Miyake K., et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14 (2001) 305-315
4. Kidani Y., Noji M., and Tashiro T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann 71 5 (1980) 637-643
5. Tashiro T., Kawada Y., Sakurai Y., and Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 43 4 (1989) 251-260
6. Kizu R., Higashi S., Kidani Y., and Miyazaki M. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31 6 (1993) 475-480
7. Mathé G., Kidani Y., Segiguchi M., Eriguchi M., Fredj G., Peytavin G., et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43 4 (1989) 237-250
8. Mathé G., Kidani Y., Triana K., Brienza S., Ribaud P., Goldschmidt E., et al. A phase I trial of trans-1-diamino-cyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 40 10 (1986) 372-376
9. De Gramont A., Buyse M., Abrahantes J.C., Burzykowski T., Quinaux E., Cervantes A., et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 25 22 (2007) 3224-3229
10. Dy G.K., Krook J.E., Green E.M., Sargent D.J., Delaunoit T., Morton R.F., et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 25 23 (2007) 3469-3474
11. Eriguchi M., Nonaka Y., Yanagie H., Yoshizaki I., Takeda Y., and Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 57 9 (2003) 412-415
12. Eriguchi M., Osada I., Fujii Y., Takeda Y., Yoshizaki I., Akiyama N., et al. Pilot study for preoperative administration of l-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother 51 5 (1997) 217-220
13. Noji M., Kizu R., Takeda Y., Akiyama N., Yoshizaki I., Eriguchi M., et al. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex. Biomed Pharmacother 59 5 (2005 Jun) 224-229
14. Bommel H., Xie G., Rossoll W., Wiese S., Jablonka S., Boehm T., et al. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol 159 (2002) 563-569
15. Martin N., Jaubert J., Gounon P., Salido E., Haase G., Szatanik M., et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat Genet 32 (2002) 443-447
16. Parvari R., Hershkovitz E., Grossman N., Gorodischer R., Loeys B., Zecic A., et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet 32 (2002) 448-452
17. Leung M.K., Jones T., Michels C.L., Livingston D.M., and Bhattacharya S. Molecular cloning and chromosomal localization of the human CITED2 gene encoding p35srj/Mrg1. Genomics 61 (1999) 307-313
18. Yanagie H., Hisa T., Tamatani T., Shimizu K., Sato E., Nitta N., et al. DNA microarray analysis specific to chemokine/chemokine receptor as the marker of metastasis in gastric cancer cell lines. In: Kitajima M., and Otani Y. (Eds). Proceeding of 6th international gastric cancer congress (2005), Medimond Press 283-286
19. Bo H., Ghazizadeh M., Shimizu H., Kurihara Y., Egawa S., Moriyama Y., et al. Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis. J Nippon Med Sch 71 3 (2004) 172-180
20. Jorgensen R.A., Cluster P.D., English J., Que Q., and Napoli C.A. Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs antisense constructs and single-copy vs complex T-DNA sequences. Plant Mol Biol 31 (1996) 957-973
21. lbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
22. Sekiguchi M., Eriguchi M., Shirota Y., Akiyama N., and Mikamo S. Chemosensitivity screening in vitro of various human cancer cell lines to a new platinum complex, l-OHP: oxalate-(trans-1-1, 2-diaminocyclo hexane) platinum(II). Ann Oncol 3 Suppl-1 (1992) 107
23. Hisa T., Yanagie H., Sakurai Y., Mouri K., Higashi S., Seguchi K., et al. Microarray analysis on human gastric tumors via laser capture microdissection. In: Kitajima M., and Otani Y. (Eds). Proceeding of 6th international gastric cancer congress (2005), Medimond Press 7-12
24. Aszalos A., and Ross D.D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res 18 (1998) 2937-2944
25. Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., et al. Taxolresistant epithelial ovarian tumors are associated with altered expression of specific h-tubulin isotypes. J Clin Invest 100 (1997) 1282-1293
26. Chen T., Pengetnze Y., and Taylor C.C. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9 independent activation of caspase-3. Mol Cancer Ther 4 (2005) 1-8
27. O'Connor D.S., Wall N.R., Porter A.C.G., and Altieri D.C. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2 (2002) 43-54
28. Yang X., Zheng F., Xing H., Gao Q., Wei W., Lu Y., et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol 130 7 (2004 Jul) 423-428
29. George J.A., Chen T., and Taylor C.C. Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 65 (2005) 10381-10388
30. Kavallaris M., Burkhart C.A., and Horwitz S.B. Antisense oligonucleotides to class III h-tubulin sensitize drugresistant cells to taxol. Br J Cancer 80 (1999) 1020-1025
31. Pengetnze Y., Steed M., Roby K.R., Terranova P.F., and Taylor C.C. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309 (2003) 377-383
32. Kortazar D., Fanarraga M.L., Carranza G., Bellido J., Villegas J.C., Avila J., et al. Role of cofactor B (TBCB) and E (TBCE) in tubulin heterodimer dissociation. Exp Cell Res 313 (2007) 425-436
33. Bartolini F., Tian G., Piehl M., Cassimeris L., Lewis S.A., and Cowan N.J. Identification of a novel tubulin-destabilizing protein related to the chaperone cofactor E. J Cell Sci 118 (2005) 1197-1207
34. Young T.W., Mei F.C., Rosen D.G., Yang G., Li N., Liu J., et al. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed proteomics analyses. Mol Cell Proteomics 6 2 (2007 Feb) 294-304
35. Chou Y.T., Wang H., Chen Y., Danielpour D., and Yang Y.C. Cited2 modulates TGF-beta-mediated upregulation of MMP9. Oncogene 25 40 (2006) 5547-5560
36. Mazure N.M., Brahimi-Horn M.C., Berta M.A., Benizri E., Bilton R.L., Dayan F., et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 68 (2004) 971-980
37. Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., and Eck M.J. Structural basis for negative regulation of hypoxia-inducible factor-1 alpha by CITED2. Nat Struct Biol 10 (2003) 504-512
38. Shioda T., Fenner M.H., and Isselbacher K.J. MSG1 and its related protein MRG1 share a transcription activating domain. Gene 204 (1997) 235-241
39. Sun H.B., Zhu Y., Sledge G., and Yang Y.C. MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcription factor with transformation activity. Proc Natl Acad Sci U S A 95 (1998) 13555-13560
40. Glenn D.J., and Maurer R.A. MRG1 binds to the LIM domain of Lhx2 and may function as a coactivator to stimulate glycoprotein hormone alpha-subunit gene expression. J Biol Chem 274 (1999) 36159-36167
41. Yin Z., Haynie J., Yang X., Han B., Kiatchoosakun S., Restivo J., et al. The essential role of Cited2, a negative regulator for HIF-1alpha, in heart development and neurulation. Proc Natl Acad Sci U S A 99 (2002) 10488-10493
42. Bamforth S.D., Braganca J., Eloranta J.J., Murdoch J.N., Marques F.I., Kranc K.R., et al. Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet 29 (2001) 469-474
43. Shioda T., Lechleider R.J., Dunwoodie S.L., Li H., Yahata T., de Caestecker M.P., et al. Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Proc Natl Acad Sci U S A 95 (1998) 9785-9790
44. Fernandez C.A., Yan L., Louis G., Yang J., Kutok J.L., and Moses M.A. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11 (2005) 5390-5395
45. Chou Y.T., and Yang Y.C. Post-transcriptional control of Cited2 by transforming growth factor β. J Biol Chem 281 (2006) 18451-18462
46. Fox S.B., Braganca J., Turley H., Campo L., Han C., Gatter K.C., et al. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1α. Cancer Res 64 (2004) 6075-6081
47. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., and Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev 13 (1999) 64-75
48. Tien E.S., Davis J.W., and Vanden Heuvel J.P. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor α coregulator. J Biol Chem 279 (2004) 24053-24063
49. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., et al. Proc Natl Acad Sci U S A 93 (1996) 12969-12973
50. De Guzman R.N., Martinez-Yamout M.A., Dyson H.J., and Wright P.E. Interaction of the TAZ1 domain of the CREB-binding protein with the activation domain of CITED2. J Biol Chem 279 (2004) 3042-3049
51. Yokota H., Goldring M.B., and Sun H.B. CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear. J Biol Chem 278 (2003) 47275-47280
52. Nolasco S., Bellido J., Goncalves J., Zabala J.C., and Soares H. Tubulin cofactor A gene silencing in mammalian cells induces changes in microtubule cytoskeleton, cell cycle arrest and cell death. FEBS Lett 579 (2005) 3515-3524
53. Loganzo F., Hari M., Annable T., Tan X., Morilla D.B., Musto S., et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in A-tubulin. Mol Cancer Ther 3 10 (2004) 1319-1327
54. Loganzo F., Discafani C.M., Annable T., Beyer C., Musto S., Hari M., et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63 (2003) 1838-1845
55. Orr G.A., Verdier-Pinard P., McDaid H., and Horwitz S.B. Mechanisms of taxol resistance related to microtubules. Oncogene 22 (2003) 7280-7295